1. Evaluation of head and neck squamous cell carcinoma invasiveness by the electrical resistance breakdown assay
   Robert Mandic et al, 2005, Clinical & Experimental Metastasis CrossRef
2. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788
   Seungwon Kim et al, 2005, Molecular Cancer Therapeutics CrossRef
3. Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study
   Leonard B. Saltz et al, 2007, Journal of Clinical Oncology CrossRef
4. Epidermal Growth Factor Receptor Biology in Head and Neck Cancer
   Shailaja Kalyankrishna et al, 2006, Journal of Clinical Oncology CrossRef
5. Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer
   Ronald M. Bukowski et al, 2007, Journal of Clinical Oncology CrossRef
6. Targeted medical therapy of biliary tract cancer: Recent advances and future perspectives
   Michael Höpfner et al, 2008, World Journal of Gastroenterology CrossRef
7. Combination Chemotherapy and Radiation of Human Squamous Cell Carcinoma of the Head and Neck Augments CTL-Mediated Lysis
   Alexander Gelbard et al, 2006, Clinical Cancer Research CrossRef
8. Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network
   John D. Hainsworth et al, 2007, Journal of Clinical Oncology CrossRef
9. Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
   Giuliano Palumbo et al, 2020, Exploration of Targeted Anti-tumor Therapy CrossRef
10. Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib
    John D. Hainsworth et al, 2005, Journal of Clinical Oncology CrossRef